CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO DAY ONE BIOPHARMACEUTICALS IF PUBLICLY DISCLOSED. ASSET PURCHASE AGREEMENT BY AND...Asset Purchase Agreement • August 2nd, 2024 • Day One Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
This ASSET PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of May 29, 2024 (the “Effective Date”) by and between [*] (“Buyer”) and DAY ONE BIOPHARMACEUTICALS, INC., a Delaware corporation (“Seller”). Buyer and Seller may hereinafter be referred to individually as a “Party” and collectively as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO DAY ONE BIOPHARMACEUTICALS, INC. IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT BY...Exclusive License Agreement • August 2nd, 2024 • Day One Biopharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Exclusive License Agreement (“Agreement”) is entered into as of June 17, 2024 (the “Effective Date”), by and between MabCare Therapeutics (上海麦科思生物医药有限公司), a company incorporated under the law of the People’s Republic of China, located at 3F, Building 1, No. 368, Xiaonan Road, Fengxian District, Shanghai, China 201401 (“MabCare”) and Day One Biopharmaceuticals, Inc., a Delaware corporation located at 395 Oyster Point Boulevard, Suite 217, South San Francisco, CA 94080, USA (“Day One”). MabCare and Day One may be referred to in this Agreement individually as a “Party” or collectively as the “Parties.”
